Skip to main content
Top
Published in: Journal of General Internal Medicine 3/2021

01-03-2021 | Statins | Original Research

Association Between Statins and Cancer Incidence in Diabetes: a Cohort Study of Japanese Patients with Type 2 Diabetes

Authors: Sadanori Okada, MD, PhD, Takeshi Morimoto, MD, PhD, Hisao Ogawa, MD, PhD, Hirofumi Soejima, MD, PhD, Chisa Matsumoto, MD, PhD, Mio Sakuma, MD, PhD, Masafumi Nakayama, MD, PhD, Naofumi Doi, MD, PhD, Hideaki Jinnouchi, MD, PhD, Masako Waki, MD, PhD, Izuru Masuda, MD, PhD, Yoshihiko Saito, MD, PhD

Published in: Journal of General Internal Medicine | Issue 3/2021

Login to get access

Abstract

Background

The antitumor effect of statins has been highlighted, but clinical study results remain inconclusive. While patients with diabetes are at high risk of cancer, it is uncertain whether statins are effective for cancer chemoprevention in this population.

Objective

This study evaluated the association between statins and cancer incidence/mortality in patients with type 2 diabetes.

Design

This study was a follow-up observational study of the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, which was a randomized controlled trial of low-dose aspirin in Japanese patients with type 2 diabetes.

Participants

This study enrolled 2536 patients with type 2 diabetes, age 30–85 years, and no history of atherosclerotic cardiovascular disease, from December 2002 until May 2005. All participants recruited in the JPAD trial were followed until the day of any fatal event or July 2015. We defined participants taking any statin at enrollment as the statin group (n = 650) and the remainder as the no-statin group (n = 1886).

Main Measures

The primary end point was the first occurrence of any cancer (cancer incidence). The secondary end point was death from any cancer (cancer mortality).

Key Results

During follow-up (median, 10.7 years), 318 participants developed a new cancer and 123 died as a result. Cancer incidence and mortality were 10.5 and 3.7 per 1000 person-years in the statin group, and 16.8 and 6.3 per 1000 person-years in the no-statin group, respectively. Statin use was associated with significantly reduced cancer incidence and mortality after adjustment for confounding factors (cancer incidence: adjusted hazard ratio [HR], 0.67; 95% CI, 0.49–0.90, P = 0.007; cancer mortality: adjusted HR, 0.60; 95% CI, 0.36–0.98, P = 0.04).

Conclusions

Statin use was associated with a reduced incidence and mortality of cancer in Japanese patients with type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082-e1143.PubMed Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082-e1143.PubMed
2.
go back to reference Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.CrossRefPubMedPubMedCentral Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.CrossRefPubMedPubMedCentral
3.
go back to reference American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103-S123. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103-S123.
4.
go back to reference Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-1802.CrossRefPubMed Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-1802.CrossRefPubMed
5.
go back to reference Kim MK, Myung SK, Tran BT, Park B. Statins and risk of cancer: a meta-analysis of randomized, double-blind, placebo-controlled trials. Indian J Cancer 2017;54:470-477.CrossRefPubMed Kim MK, Myung SK, Tran BT, Park B. Statins and risk of cancer: a meta-analysis of randomized, double-blind, placebo-controlled trials. Indian J Cancer 2017;54:470-477.CrossRefPubMed
6.
go back to reference Sopkova J, Vidomanova E, Strnadel J, Skovierova H, Halasova E. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys 2017;36:501-511.CrossRefPubMed Sopkova J, Vidomanova E, Strnadel J, Skovierova H, Halasova E. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys 2017;36:501-511.CrossRefPubMed
7.
go back to reference Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance-the antagonistic drug-drug interactions versus the anti-cancer effects. Biomed Pharmacother 2018;108:1856-1865.CrossRefPubMed Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance-the antagonistic drug-drug interactions versus the anti-cancer effects. Biomed Pharmacother 2018;108:1856-1865.CrossRefPubMed
8.
9.
go back to reference Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.CrossRef Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.CrossRef
11.
go back to reference Wang A, Aragaki AK, Tang JY, et al. Statin use and all-cancer survival: prospective results from the Women’s Health Initiative. Br J Cancer 2016;115:129-135.CrossRefPubMedPubMedCentral Wang A, Aragaki AK, Tang JY, et al. Statin use and all-cancer survival: prospective results from the Women’s Health Initiative. Br J Cancer 2016;115:129-135.CrossRefPubMedPubMedCentral
13.
go back to reference Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010;24:345-353.CrossRefPubMed Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010;24:345-353.CrossRefPubMed
14.
go back to reference Emerging Risk Factors C, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.CrossRef Emerging Risk Factors C, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.CrossRef
15.
go back to reference Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetology International 2013;4:81-96.CrossRef Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetology International 2013;4:81-96.CrossRef
16.
go back to reference Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017;8:397-410.CrossRefPubMedPubMedCentral Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017;8:397-410.CrossRefPubMedPubMedCentral
17.
go back to reference Okada S, Morimoto T, Ogawa H, et al. Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial. Diabetes Care 2018;41:1757-1764.CrossRefPubMed Okada S, Morimoto T, Ogawa H, et al. Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial. Diabetes Care 2018;41:1757-1764.CrossRefPubMed
18.
go back to reference Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141.CrossRefPubMed Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141.CrossRefPubMed
19.
go back to reference Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017;135:659-670.CrossRefPubMed Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017;135:659-670.CrossRefPubMed
20.
go back to reference Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004;45 Suppl 2:S3-9.CrossRefPubMed Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004;45 Suppl 2:S3-9.CrossRefPubMed
23.
go back to reference Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 2016;27:2184-2195.CrossRefPubMedPubMedCentral Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 2016;27:2184-2195.CrossRefPubMedPubMedCentral
24.
go back to reference Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med 2019;36:22-35.CrossRefPubMed Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med 2019;36:22-35.CrossRefPubMed
25.
go back to reference Asano K, Kubo M, Yonemoto K, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer 2008;122:909-914.CrossRefPubMed Asano K, Kubo M, Yonemoto K, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer 2008;122:909-914.CrossRefPubMed
26.
go back to reference Iso H, Ikeda A, Inoue M, Sato S, Tsugane S, Group JS. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009;125:2679-2686.CrossRefPubMed Iso H, Ikeda A, Inoue M, Sato S, Tsugane S, Group JS. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009;125:2679-2686.CrossRefPubMed
27.
go back to reference Nago N, Ishikawa S, Goto T, Kayaba K. Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol 2011;21:67-74.CrossRefPubMedPubMedCentral Nago N, Ishikawa S, Goto T, Kayaba K. Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol 2011;21:67-74.CrossRefPubMedPubMedCentral
28.
go back to reference Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008;179:427-437.CrossRefPubMedPubMedCentral Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008;179:427-437.CrossRefPubMedPubMedCentral
30.
31.
go back to reference Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009;32:1826-1832.CrossRefPubMedPubMedCentral Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009;32:1826-1832.CrossRefPubMedPubMedCentral
32.
go back to reference Iannelli F, Lombardi R, Milone MR, et al. Targeting mevalonate pathway in cancer treatment: repurposing of statins. Recent Pat Anticancer Drug Discov 2018;13:184-200.CrossRefPubMed Iannelli F, Lombardi R, Milone MR, et al. Targeting mevalonate pathway in cancer treatment: repurposing of statins. Recent Pat Anticancer Drug Discov 2018;13:184-200.CrossRefPubMed
33.
go back to reference Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol 2015;11:372-379.CrossRefPubMed Yang X, Lee HM, Chan JC. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. Nat Rev Endocrinol 2015;11:372-379.CrossRefPubMed
34.
go back to reference Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how? Diabetes Obes Metab 2012;14:579-585.CrossRefPubMed Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how? Diabetes Obes Metab 2012;14:579-585.CrossRefPubMed
Metadata
Title
Association Between Statins and Cancer Incidence in Diabetes: a Cohort Study of Japanese Patients with Type 2 Diabetes
Authors
Sadanori Okada, MD, PhD
Takeshi Morimoto, MD, PhD
Hisao Ogawa, MD, PhD
Hirofumi Soejima, MD, PhD
Chisa Matsumoto, MD, PhD
Mio Sakuma, MD, PhD
Masafumi Nakayama, MD, PhD
Naofumi Doi, MD, PhD
Hideaki Jinnouchi, MD, PhD
Masako Waki, MD, PhD
Izuru Masuda, MD, PhD
Yoshihiko Saito, MD, PhD
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 3/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06167-5

Other articles of this Issue 3/2021

Journal of General Internal Medicine 3/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.